Audits Increase as Injections Increase – Retinal Physician
Prepare for the inevitable with proper documentation.
Injectable drugs for retinal disease — particularly ranibizumab (Lucentis; Genentech) and aflibercept (Eylea; Regeneron) — are the focus of audits for Medicare and other payers. How can you avoid problems?
This article addresses the following questions:
- Why does Medicare devote so much attention to anti-VEGF drugs?
- What documentation is required to support claims for anti-VEGF drugs?
- Why does Medicare use a 28-day interval between injections?
- What audits are currently active?
- How should we respond to a TPE or other audit?
- How can we protect ourselves from an audit?
This article was published in Retinal Physician, which is written by Corcoran’s Executive Vice-President, Suzanne Corcoran, COE. To view the entire article in Retinal Physician, click on the link below: